Sürig Ulf, Gaal Klaudia, Kostenis Evi, Tränkle Christian, Mohr Klaus, Holzgrabe Ulrike
Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany.
Arch Pharm (Weinheim). 2006 Apr;339(4):207-12. doi: 10.1002/ardp.200600005.
Allosteric modulators of receptor binding are known for a variety of membrane receptors. In case of muscarinic receptors, a considerable number of structurally divergent modulators have been described. For the M2 receptor subtype which has a high sensitivity to allosteric modulation most of the allosteric agents bind to the common allosteric binding site of the receptor protein. In this study, a series of DUO compounds characterized by a bispyridinium middle chain and lateral benzyloximeether moieties of a systematically varied substitution pattern has been evaluated with regard to their allosteric potency to affect M2 receptors, whose orthosteric site was blocked by [3H]N-methylscopolamine. The variations in potency were found to be surprisingly small and the structure-activity relationships of the DUO compounds diverged from those of correspondingly substituted hexamethonio-type allosteric modulators. One has to conclude that DUO compounds bind in an "atypical" manner which is in agreement with recently reported side-directed mutagenesis and molecular modeling studies.
受体结合的变构调节剂在多种膜受体中都有发现。就毒蕈碱受体而言,已经描述了大量结构不同的调节剂。对于对变构调节高度敏感的M2受体亚型,大多数变构剂都与受体蛋白的共同变构结合位点结合。在本研究中,一系列以双吡啶鎓中间链和具有系统变化取代模式的侧基苄基肟醚部分为特征的DUO化合物,针对其影响M2受体的变构效力进行了评估,该受体的正构位点被[3H]N-甲基东莨菪碱阻断。发现效力变化惊人地小,并且DUO化合物的构效关系与相应取代的六甲铵型变构调节剂的构效关系不同。人们不得不推断,DUO化合物以“非典型”方式结合,这与最近报道的侧链定向诱变和分子建模研究一致。